JPRN-UMIN000020315尚未招募2 期
A pahse 2 study of bortezomib monotherapy for Epstein-Barr virus positive T or NK cell lymphoproliferative disease (Chronic active Epstein-Barr virus infection) - A pahse 2 study of bortezomib monotherapy for EBV-T/NK-LPD (CAEBV)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 69years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Need for radiation more than 15 Gy including palliation at the time of registration (2) Uncontrollable hypertension (3) History of myocardial infarction or angina or cardiomyopathy (4) HBs antigen positive (5) Severe infection except EBV (6) Liver cirrhosis, either biopsy proven or clinically diagnose (7) Active double cancer: overlapping cancer or asynchronous cancer within 5 years. Carcinoma in situ, intramucosal cancers, and other equivalent lesions are not included for the active double cancer. (8) Women during pregnancy, lactation period or of childbearing potentials not using a reliable contraceptive method (9) Use of major tranquilizer, antidepressant, or antimanic (10) Severe psychosis
研究者
相似试验
已完成
不适用
Phase II study of bortezomib maintenance therapy for multiple myeloma patientsMultiple MyelomaJPRN-UMIN000013912ational Hospital Organization Disaster Medical Center of Japan96
进行中（未招募）
1 期
A study to investigated whether bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-DEHOVON Foundation50
已完成
不适用
Phase I study of weekly bortezomib for patients with recurrent or refractory multiple myelomaMultiple myelomaJPRN-UMIN000002922PO IB-HOPE12
进行中（未招募）
1 期
A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-NLHOVON Foundation50
进行中（未招募）
1 期
A Phase 2 Relapsed or Refractory Multiple Myeloma trial - with orwithout Elotuzumab.Relapsed or Refractory Multiple MyelomaMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002695-16-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO150